An integrated strategy to identify inhibitors of protein-protein interactions as potential therapeutics for Parkinson's disease

确定蛋白质-蛋白质相互作用抑制剂作为帕金森病潜在疗法的综合策略

• 批准号: 380936
• 负责人: Kalia Lorraine V
• 金额: $ 104.77万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-03-01 至 2023-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=380936&lang=en
• 关键词: Alpha-Synuclein; High-Throughput Screen; Neurodegeneration; Parkinson'S Disease; Peptide Inhibitors; Pooled Lentiviral Screen; Protein Aggregation; Protein-Protein Interactions; Rat Model; Yeast Model

Parkinson's disease is a common and disabling neurological disorder that is increasing in prevalence and thus having a growing impact on the Canadian population. The disease results from a process, called neurodegeneration, in which certain brain cells di

帕金森氏病是一种常见的致残性神经系统疾病，其患病率正在增加，因此对加拿大人口的影响越来越大。这种疾病是由一种叫做神经变性的过程引起的，在这种过程中，某些脑细胞死亡，